Results 11 to 20 of about 71,002 (280)

The Poly(ADP-ribose) polymerase inhibitors in pancreatic cancer

open access: yesNowotwory, 2022
Genome instability and mutations are the hallmarks of cancer. Mutations within BRCA genes increase the risk of pancreatic cancer (PC) development. Poly(ADP-ribose) polymerase inhibitors (PARPi) show the synthetic lethality phenomenon in tumoral cells ...
Katarzyna Zubik   +3 more
doaj   +3 more sources

The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas [PDF]

open access: yesJournal of Immunotherapy and Precision Oncology, 2020
Diffuse infiltrating gliomas are a clinically and molecularly heterogeneous group of tumors that are uniformly incurable. Despite our growing knowledge of genomic and epigenomic alterations in gliomas, standard treatments have not changed in the past 2 ...
Nazanin Majd   +3 more
doaj   +4 more sources

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy [PDF]

open access: yesFrontiers in Pharmacology, 2020
Poly(ADP-ribose)polymerase-1 (PARP1) is a DNA repair enzyme highly expressed in the nuclei of mammalian cells, with a structure and function that have attracted interest since its discovery.
Stephen A. Jannetti   +10 more
doaj   +3 more sources

Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer

open access: yesTaiwanese Journal of Obstetrics & Gynecology, 2017
Chia-Hao Liu, Yi Chang
doaj   +3 more sources

Poly(ADP-Ribose) Polymerase Inhibitors [PDF]

open access: yesJournal of Thoracic Oncology, 2010
This session not only described several poly(ADP-ribose) polymerase (PARP) inhibitors but also included talks on the science of nuclear excision repair, an oxidized glutathione, and a heat shock protein (HSP) 90 inhibitor. SUMMARY OF PRESENTATIONS Science of Nuclear Excision Repair Dr.
Garon, Edward B., Dubinett, Steven M.
openaire   +4 more sources

Pyridazine Based Compounds with PARP-1 Inhibitory Activity

open access: yesArchives of Pharmaceutical Sciences Ain Shams University, 2023
Pyridazine-containing compounds have been identified as potent PARP1 inhibitors. The PARP is a family of enzymes essential for many cellular processes such as DNA repair, genomic stability, and apoptosis, also known as poly(ADP-ribose) synthetases and ...
Norhan A. Abdelrahman   +3 more
doaj   +1 more source

5mC-hydroxylase activity is influenced by the PARylation of TET1 enzyme [PDF]

open access: yes, 2015
5-hydroxymethylcytosine is a new epigenetic modification deriving from the oxidation of 5-methylcytosine by the TET hydroxylase enzymes. DNA hydroxymethylation drives DNA demethylation events and is involved in the control of gene expression ...
CAIAFA, Paola   +3 more
core   +12 more sources

The potential role of the combined PARP-1 and VEGF inhibition in severe SARS-CoV-2 (COVID-19) infection

open access: yesJournal of Infection in Developing Countries, 2022
Introduction: During the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several drug candidates have been proposed for repositioning towards a quest for more effective treatments.
Dimitra Ioanna Lampropoulou   +6 more
doaj   +1 more source

Adverse events of targeted therapies approved for women's cancers

open access: yesInternational Journal of Women's Dermatology, 2021
Breast cancer and gynecologic cancers affect >3 million women worldwide each year. With advances in precision medicine, a growing number of targeted therapies have been approved recently, and new therapeutic classes have emerged, including cell cycle ...
Mathilde Saint-Ghislain, MD   +2 more
doaj   +1 more source

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer

open access: yesBMC Cancer, 2020
Background Poly (ADP-ribose) polymerase inhibitors targeting BRCA1/2 mutations are available for treating patients with high-grade serous ovarian cancer.
Kyung Jin Eoh   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy